Omega Therapeutics IPO Presentation Deck

EpiZips and OECs The OMEGA platform enables targeting of EpiZips within and across IGDs for Precision Genomic Control OECs: mRNA-encoded epigenetic medicines Omega's proprietary DNA-binding domain Linker 2021 Omega Therapeutics, Inc. Epigenomic effector protein Key Advantages mRNA-encoded proteins delivered in LNP High specificity, tunability and durability Multiplexed single or multiple gene control No changes in nucleic acid sequences OEC 1 Promoter- Brampe p HEP 20Xv2623 Enhancer/ Repressor Example 2 HSP 204x Y.2824) OEC 2 OEC 3 IGD and EpiZips CTCF xemple Epizo HP 20qX.V.2.625) DNA Gene IGD

View entire presentation